Athira Pharma, Inc.
ATHA
$4.14
-$0.08-1.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.63M | 5.23M | 6.20M | 7.57M | 5.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.29M | 9.54M | 15.57M | 25.49M | 28.03M |
| Operating Income | -7.29M | -9.54M | -15.57M | -25.49M | -28.03M |
| Income Before Tax | -6.97M | -9.14M | -15.00M | -28.74M | -26.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.97M | -9.14M | -15.00M | -28.74M | -26.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.97M | -9.14M | -15.00M | -28.74M | -26.86M |
| EBIT | -7.29M | -9.54M | -15.57M | -25.49M | -28.03M |
| EBITDA | -7.05M | -9.29M | -15.32M | -25.25M | -27.79M |
| EPS Basic | -1.78 | -2.34 | -3.88 | -7.46 | -7.00 |
| Normalized Basic EPS | -1.11 | -1.47 | -2.43 | -3.99 | -4.37 |
| EPS Diluted | -1.78 | -2.34 | -3.88 | -7.46 | -7.00 |
| Normalized Diluted EPS | -1.11 | -1.47 | -2.43 | -3.99 | -4.37 |
| Average Basic Shares Outstanding | 3.91M | 3.90M | 3.87M | 3.85M | 3.84M |
| Average Diluted Shares Outstanding | 3.91M | 3.90M | 3.87M | 3.85M | 3.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |